Meeting
2023 ASCO Annual Meeting
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
Authors
Piyush Grover
Melanoma Institute Australia, Sydney, Australia
Piyush Grover , Isabel Li , Anke Kuijpers , Firas Y. Kreidieh , Andrew Williamson , Teresa Maria Santos Amaral , Florentia Dimitriou , Joanna Placzke , Kelly Olino , Maria Grazia Vitale , Philippe Saiag , Ralf Gutzmer , Clara Allayous , Roger Olofsson Bagge , Nethanel Asher , Tarek Meniawy , Aleigha Lawless , Lydia Warburton , Alexander M. Menzies , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9518)
DOI
10.1200/JCO.2023.41.16_suppl.9518
Abstract #
9518
Poster Bd #
281
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of "second adjuvant" therapy with BRAF/MEK inhibitors after resection of recurrent melanoma following adjuvant PD-1–based immunotherapy.
First Author: Amelia M. Taylor
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown
Poster
2022 ASCO Annual Meeting
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
First Author: Minke W. Lucas
Poster
2022 ASCO Annual Meeting
Progression and mortality post-immunotherapy discontinuation among patients with BRAFV600-mutant (BRAF+) metastatic melanoma.
First Author: Sunandana Chandra